Ethanol in tears can cause development of ocular diseases

Article

Orally administered ethanol is secreted into tears and can cause the development of ocular surface diseases.

Orally administered ethanol is secreted into tears and can cause the development of ocular surface diseases, claims a study in the journal Ophthalmology.

The case control study, led by Dr Joo Hyun Kim, Department of Ophthalmology, Hallym University College of Medicine, Seoul, Korea, included 20 healthy male subjects with no prior ocular surface diseases. Ten participants received ethanol orally at 8 pm for two hours and ten were placed in the control group.

The main outcome measures were tear osmolarity, ethanol concentration in tears and serum, Schirmer's test results, tear film break-up time (TBUT), corneal punctuate erosion and corneal sensitivity. Tear film and ocular surface were measured at 6 pm before drinking, at midnight and at 6 am and 8 am the following morning.

Mean tear osmolarity increased in the ethanol group, compared to the control group. The ethanol group demonstrated a significantly shorter TBUT after drinking alcohol.

The fluorescein staining scores were significantly higher in the alcohol group compared to the control group at 6 am and 8 am. However, there were no changes in corneal sensitivity or Schirmer's test results.

Ethanol in tears caused the development hyperosmolarity and reduced TBUT. These changes could worsen signs and symptoms in patients with ocular surface disease.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.